Imugene (AU:IMU)

ASX:IMU

IMU

Imugene

RESEARCH TOOLSreports

Want to see AU:IMU full AI Analyst Report?

Imugene (IMU) Price & Analysis

145 Followers

IMU Stock Chart & Stats

AU$0.33

>-AU$0.01(-2.22%)

At close: Jan 09 4:00 PM EST

AU$0.33

>-AU$0.01(-2.22%)

Day’s Range― - ―

52-Week RangeAU$0.12 - AU$0.92

Previous CloseN/A

Volume11.90M

Average Volume (3M)877.83K

Market Cap

AU$50.23M

Enterprise ValueAU$35.52M

Total Cash (Recent Filing)AU$14.14M

Total Debt (Recent Filing)AU$5.02M

Price to Earnings (P/E)―

Beta1.88

Next Earnings

Aug 28, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.13

Shares Outstanding372,105,470

10 Day Avg. Volume850,615

30 Day Avg. Volume877,834

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)2.15

Price to Sales (P/S)21.99

P/FCF Ratio-1.07

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.18

Revenue Forecast (FY)AU$5.00M

Bulls Say, Bears Say

Bulls Say

Conservative Balance SheetA low debt-to-equity ratio (0.24) and equity ratio near 54% indicate conservative leverage and a moderate equity base. That structure provides financial flexibility to fund multi-stage clinical programs, reduces interest burden risk, and preserves optionality for partnerships or raises.

Pipeline DiversityImugene's portfolio spans an oncolytic virus platform (CF33) and vaccine approaches (PD1-Vaxx, HER-Vaxx). Multiple modalities and clinical-stage programs spread scientific and development risk, increasing the likelihood of at least one value-creating outcome and multiple partnering/licensing paths.

High Gross Margin ProfileA reported 100% gross profit margin implies negligible COGS typical for clinical-stage biologics and services. If candidates commercialize, product-level economics could be highly scalable, supporting strong incremental profitability as revenue ramps and amplifying long-term operating leverage benefits.

Bears Say

Revenue CollapseA year-over-year revenue decline of -338.95% reflects essentially no recurring commercial sales and a deteriorated revenue base. This forces reliance on external financing or deals to sustain R&D, compresses operational runway, and undermines the firm's ability to self-fund clinical progression over the medium term.

Negative Profitability & ROEDeep negative margins and a ROE of -153% show the company is destroying shareholder value through operating losses. Persistent unprofitability erodes equity, deters long-term capital providers, raises the likelihood of dilution, and constrains strategic flexibility absent clear clinical inflection points.

Weak Operating Cash GenerationNegative operating cash flow versus net income indicates operations are consuming cash. Continued weak cash generation forces dependence on equity raises or partner funding, increasing dilution risk and potentially delaying trials or development milestones if fresh non-dilutive funding cannot be secured.

Imugene News

Imugene Seeks ASX Quotation for 15 Million New Shares

Imugene ( ($AU:IMU) ) just unveiled an announcement. Imugene Limited has applied to the ASX for quotation of...

2d ago

Imugene Secures $16m Funding as Shareholders Back Capital Raising

Imugene ( ($AU:IMU) ) has issued an update. Imugene Limited has secured strong shareholder backing at its Extraordinary...

3d ago

Imugene CEO Leslie Chong Increases Direct Shareholding via On-Market Purchase

Imugene ( ($AU:IMU) ) just unveiled an announcement. Imugene chief executive Leslie Chong has increased her direct holding...

3d ago

Imugene Cuts Potential Dilution as Expired Options and Rights Lapse

An update from Imugene ( ($AU:IMU) ) is now available. Imugene Limited has notified the market of the...

15d ago

Imugene applies for ASX quotation of additional ordinary shares

Imugene ( ($AU:IMU) ) has issued an announcement. Imugene Limited has applied to the ASX for quotation of...

17d ago

Imugene Issues Additional Unquoted Options as Part of Ongoing Capital Management

The latest announcement is out from Imugene ( ($AU:IMU) ). Imugene Limited has notified the market of the...

23d ago

Imugene Seeks ASX Quotation for Shares Issued on Option Conversions

Imugene ( ($AU:IMU) ) has provided an announcement. Imugene Limited has applied to the ASX for quotation of...

24d ago

Imugene’s Lead CAR T Therapy Azer-cel Wins Prestigious ASCO 2026 Oral Slot

Imugene ( ($AU:IMU) ) has provided an update. Imugene announced that new data from its lead CAR T...

25d ago

Imugene’s PD1-Vaxx Lung Cancer Trial Ends Early: What Investors Should Know

Imugene Ltd ($IUGNF) announced an update on their ongoing clinical study. The IMU-201 (PD1-Vaxx) IMPrinter trial, officially titled...

1M ago

IUGNF

Imugene calls hybrid Extraordinary General Meeting with expanded online access

The latest update is out from Imugene ( ($AU:IMU) ). Imugene Limited has called an Extraordinary General Meeting...

1M ago

IMU FAQ

What was Imugene’s price range in the past 12 months?

Imugene lowest share price was AU$0.12 and its highest was AU$0.92 in the past 12 months.

What is Imugene’s market cap?

Imugene’s market cap is AU$50.23M.

When is Imugene’s upcoming earnings report date?

Imugene’s upcoming earnings report date is Aug 28, 2026 which is in 125 days.

How were Imugene’s earnings last quarter?

Imugene released its earnings results on Feb 25, 2026. The company reported -AU$0.13 earnings per share for the quarter, beating the consensus estimate of -AU$0.34 by AU$0.21.

Is Imugene overvalued?

According to Wall Street analysts Imugene’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Imugene pay dividends?

Imugene does not currently pay dividends.

What is Imugene’s EPS estimate?

Imugene’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Imugene have?

Imugene has 372,105,470 shares outstanding.

What happened to Imugene’s price movement after its last earnings report?

Imugene reported an EPS of -AU$0.13 in its last earnings report, beating expectations of -AU$0.34. Following the earnings report the stock price went down -5.882%.

Which hedge fund is a major shareholder of Imugene?

Currently, no hedge funds are holding shares in AU:IMU

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Imugene Stock Smart Score

Neutral

Fundamentals

Return on Equity

-134.65%

Trailing 12-Months

Asset Growth

-39.73%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Imugene

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.